top of page

Catch more cancers early with health checkups

A single blood test for healthy individuals to assess risks for early-stage cancers when they are most curable

Cancer is the #1 cause of death in people ages 35-75 years old in developed countries. 

A new way to proactively uncover cancers early before they become symptomatic 

A potential shared pattern of 12+ cancers

miRoncol identify a presumably shared pattern from 12+ types of solid tumors that are accountable for ~60% of total cancer death today.

Non-invasive and convenient

miRoncol's technology is a blood test that can be prescribed by physicians for regular checkups.

Suprior performance

miRoncol's technology can expose signals from early stage cancers accurately while keep false positive rate very low.

More affordable

miRoncol's technology doesn't introduce any new equipememnt. It uses globally available platform PCR that can be much more affordable then alternative solutions and reach more people in need.

miRNA based technology

Discovery of microRNA(miRNA) won the 2024 Nobel Prize in Medicine

Promising biomarkers for disease diagnosis and prognosis

Check out 1-min video about miRNA

Basic Properties
  • Discovered in 1993

  • Short single-stranded

  • Stable and detectable in blood

Functions
  • Non-coding

  • Regulate gene expression

  • Different expression profile in cancer patients

Scientific rigor

Publications

Publications

Peer-reviewed publications
Scientific Reports Logo_White.png

Noninvasive multi-cancer detection using blood-based cell-free microRNAs

Cancer_white.png

A Novel Blood-Based microRNA Diagnostic Model with High Accuracy for Multi-Cancer Early Detection

Presentations

Poster presentation at the 2024 Early Detection of Cancer Conference

Poster presentation at 2022 Annual Meeting of American Society of Clinical Oncology.​

Poster presentation at the 2024 ASCO Breakthrough and won the abstract award.​

Poster presentation at the 2022 Annual Meeting of American Association for Cancer Research.

Poster presentation at 2023 European Society for Medical Oncology Congress Meeting​

At the 2021 World Conference on Lung Cancer, our study was not only selected for oral presentation, but also highlighted in the Meeting News.​​

Recurring
Real-time
Risk assessment tool

to enable more people to catch cancers early in health checkups.
Accurate+Affordable+Accessible

Most early-stage solid tumors are incidental findings through various imaging tools instead of cancer screening. Catching cancers early significantly improves treatment outcomes, increases long-term survival rates, and often allows for less invasive and more effective treatment options.

​​

miRoncol is dedicated to bringing a category-defining tool to provide more certainty to people rather than praying for luck to identify their silently growing cancers incidentally. 

miRoncol 400dpiLogoCroppedNewColor
miRoncol â„¢

A miracle in oncology made possible with miRNA

1000 Innovation Dr., 5F

Ottawa, ON K2K 3E7, Canada

​

DISCLAIMER

This website may contain certain statements, estimations, projections, assessments and other information with respect to the anticipated future performance of the Company and/or its market and involve risks and uncertainties. Actual results or future business decisions of the Company may differ materially from any expectations, projections or predictions made or implicated in statements made in this website. While the Company believes that the information contained herein is accurate, it expressly disclaims any and all liability for representations or warranties, expressed or implied, contained in, or for omissions from, this website or any other communication transmitted or made available herein. Any prospective website user acknowledges his/her responsibility to perform a due diligence review prior to consummating a transaction with the Company. Included in this website are certain declarations by the Company with respect to its anticipated future performance. These declarations are based on estimates and assumptions by the Company that are subject to economic and competitive uncertainties beyond the control of the Company. The Company does not provide representation or warranty with regard to the declarations and there can be no assurance that the future results will be realized or that actual results will not be significantly different from those projected. The Company is not obligated to update or revise any future declarations. The Company and its respective affiliates, directors, officers, employees, consultants and representatives expressly disclaim any and all liability relating to or resulting from the utilization of any information contented in this website. The Company does not have any obligation to provide with access to additional information.

© 2021 - 2025 by miRoncol ™. All rights reserved.

bottom of page